A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

Drug Category: Array
Conference Category: Array
Lead Author: Sawas, O'Connor et al.
Published Date: 16/12/2016
Download Link: http://onlinelibrary.wiley.com/doi/10.1111/bjh.14534/full
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top